Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Anne Corbett; Gareth Williams; Clive Ballard

doi:10.3390/ph6101304

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Anne Corbett, Gareth Williams, Clive Ballard

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.

Original language	English
Article number	N/A
Pages (from-to)	1304-1321
Number of pages	18
Journal	Pharmaceuticals
Volume	6
Issue number	10
DOIs	https://doi.org/10.3390/ph6101304
Publication status	Published - Oct 2013

Keywords

Acknowledged-BRU
Acknowledged-BRU-13/14
Acknowledged-BRC

Access to Document

10.3390/ph6101304

Cite this

@article{8d644daa2c70474f8d75d92ebb1af724,

title = "Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer{\textquoteright}s Disease",

abstract = "Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.",

keywords = "Acknowledged-BRU, Acknowledged-BRU-13/14, Acknowledged-BRC",

author = "Anne Corbett and Gareth Williams and Clive Ballard",

year = "2013",

month = oct,

doi = "10.3390/ph6101304",

language = "English",

volume = "6",

pages = "1304--1321",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Drug Repositioning

T2 - An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

AU - Corbett, Anne

AU - Williams, Gareth

AU - Ballard, Clive

PY - 2013/10

Y1 - 2013/10

N2 - Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.

AB - Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.

KW - Acknowledged-BRU

KW - Acknowledged-BRU-13/14

KW - Acknowledged-BRC

U2 - 10.3390/ph6101304

DO - 10.3390/ph6101304

M3 - Article

C2 - 24275851

SN - 1424-8247

VL - 6

SP - 1304

EP - 1321

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 10

M1 - N/A

ER -

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this